Substance / Medication

Daptomycin

Overview

Active Ingredient
daptomycin
RxNorm CUI
22299
Labeler: Meitheal Pharmaceuticals Inc.Updated: 2026-02-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Warnings and Precautions (5.1) [see] Daptomycin for Injection is contraindicated in patients with known hypersensitivity to daptomycin.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis.
Boulekbache Abdelwahab, Maldonado Fanny, Kavafian Raphael et al. · J Antimicrob Chemother · 2024
PMID: 38323372Meta-Analysis
Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series.
Gidari Anna, Pallotto Carlo, Francisci Daniela · Infection · 2024
PMID: 39028390Meta-AnalysisFull text (PMC)
Daptomycin-Induced Eosinophilic Pneumonia: A Case Report and Systematic Review.
Di Lorenzo Andrea, Rindi Lorenzo Vittorio, Campogiani Laura et al. · Chemotherapy · 2024
PMID: 37963447Meta-Analysis
Daptomycin as an option for lock therapy: a systematic literature review.
Tzalis Sotirios, Ioannou Petros, Billiari Eleni et al. · Future Microbiol · 2023
PMID: 37622290Meta-Analysis
[Efficacy and safety of daptomycin in the treatment of gram-positive infective endocarditis: a meta-analysis].
Ge Y, Zhou J, Ma X J · Zhonghua Yi Xue Za Zhi · 2023
PMID: 36649992Meta-Analysis
The impact of daptomycin therapeutic drug monitoring on clinical outcomes: a systematic review.
Cairns Kelly A, Abbott Iain J, Dooley Michael J et al. · Int J Antimicrob Agents · 2023
PMID: 36640849Meta-Analysis
Comparison of the efficacy and safety of standard- and high-dose daptomycin: A systematic review and meta-analysis.
Samura Masaru, Takada Keisuke, Hirose Naoki et al. · Br J Clin Pharmacol · 2023
PMID: 36693240Meta-Analysis
Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis.
Samura Masaru, Takada Keisuke, Hirose Naoki et al. · Br J Clin Pharmacol · 2022
PMID: 34902879Meta-Analysis
Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM.
Matsumoto Kazuaki, Samura Masaru, Tashiro Sho et al. · Biol Pharm Bull · 2022
PMID: 35786589Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Daptomycin (substance)
SNOMED CT
406439009
UMLS CUI
C0057144
RxNorm CUI
22299
Labeler
Meitheal Pharmaceuticals Inc.

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.